ABT-751Phase II
Tubulin beta inhibitor
AGS-16C3FPhase II
Tubulin disrupting agent
renal cell carcinoma
ANETUMAB RAVTANSINEPhase II
Tubulin inhibitor
malignant pleural mesothelioma
ANG1005Phase II
Tubulin inhibitor
ANVATABART OPADOTINPhase II/III
Tubulin inhibitor
HER2 Positive Breast Carcinoma
APRUTUMAB IXADOTINPhase I
Fibroblast growth factor receptor 2 binding agent
cancer
ASG-5MEPhase I
Choline transporter-like protein 4 binding agent
Malignant Pancreatic Neoplasm
AVE-9633Phase I
Myeloid cell surface antigen CD33 binding agent
myeloid leukemia
AZINTUXIZUMAB VEDOTINPhase I
SLAM family member 7 binding agent
multiple myeloma
BELANTAMAB MAFODOTINApproved
Tumor necrosis factor receptor superfamily member 17 binding agent
multiple myeloma
BIIB-015Phase I
Teratocarcinoma-derived growth factor 1 binding agent
BIVATUZUMAB MERTANSINEUNKNOWN
Tubulin inhibitor
BMS-275183Phase II
Tubulin stabiliser
BRENTUXIMAB VEDOTINApproved
Tubulin inhibitor
CABAZITAXELApproved
Tubulin inhibitor
prostate cancer
CANTUZUMAB MERTANSINEPhase II
Tubulin inhibitor
non-small cell lung carcinoma
CANTUZUMAB RAVTANSINEPhase II
Mucin-1 binding agent
stomach neoplasm
COLCHICINEApproved
Tubulin inhibitor
familial Mediterranean fever
COLTUXIMAB RAVTANSINEPhase II
Tubulin inhibitor
diffuse large B-cell lymphoma
CROLIBULINPhase I/II
Tubulin inhibitor
DAVUNETIDEPhase III
Tubulin stabiliser
Cognitive impairment
DENINTUZUMAB MAFODOTINPhase II
B-lymphocyte antigen CD19 binding agent
diffuse large B-cell lymphoma
DEPATUXIZUMAB MAFODOTINPhase III
Epidermal growth factor receptor erbB1 binding agent
glioblastoma multiforme
DISITAMAB VEDOTINPhase III
Receptor tyrosine-protein kinase erbB-2 binding agent
breast cancer
DOCETAXELApproved
Tubulin inhibitor
DOCETAXEL ANHYDROUSApproved
Tubulin stabiliser
prostate cancer
DOLASTATIN-10Phase II
Tubulin inhibitor
ENAPOTAMAB VEDOTINPhase I/II
Tyrosine-protein kinase receptor UFO binding agent
ENFORTUMAB VEDOTINApproved
Nectin-4 binding agent
EPOTHILONE DPhase II
Tubulin stabiliser
breast cancer
ERIBULINApproved
Tubulin inhibitor
breast cancer
ERIBULIN MESYLATEApproved
Tubulin inhibitor
breast cancer
FOSBRETABULINPhase III
Tubulin disrupting agent
thyroid cancer
FOSBRETABULIN DISODIUMPhase II
Tubulin inhibitor
neuroendocrine carcinoma
FOSBRETABULIN TROMETHAMINEPhase II/III
Tubulin disrupting agent
ovarian cancer
GLEMBATUMUMAB VEDOTINApproved
Transmembrane glycoprotein NMB binding agent
lymphoma
IMGN-388Phase I
Vitronectin receptor alpha binding agent
INDATUXIMAB RAVTANSINEPhase II
Syndecan-1 binding agent
multiple myeloma
INDIBULINPhase II
Tubulin inhibitor
INDUSATUMAB VEDOTINPhase II
Heat-stable enterotoxin receptor binding agent
IXABEPILONEApproved
Tubulin inhibitor
breast cancer
KOS-1584Phase II
Tubulin stabiliser
non-small cell lung carcinoma
LADIRATUZUMAB VEDOTINPhase II
Zinc transporter ZIP6 binding agent
breast cancer
LAROTAXELPhase III
Tubulin stabiliser
urinary bladder carcinoma
LEXIBULINPhase II
Tubulin inhibitor
glioblastoma multiforme
LIFASTUZUMAB VEDOTINPhase II
Sodium-dependent phosphate transport protein 2B binding agent
ovarian cancer
LORVOTUZUMAB MERTANSINEPhase II
Neural cell adhesion molecule 1 binding agent
MECBOTAMAB VEDOTINPhase II
Tyrosine-protein kinase receptor UFO binding agent
ovarian cancer
MILATAXELPhase II
Tubulin inhibitor
MIRVETUXIMAB SORAVTANSINEApproved
Folate receptor alpha binding agent
ovarian cancer
MLN-2704Phase I/II
Glutamate carboxypeptidase II binding agent
prostate cancer
OMBRABULINPhase III
Tubulin inhibitor
sarcoma
PACLITAXELApproved
Tubulin inhibitor
PACLITAXEL DOCOSAHEXAENOIC ACIDPhase III
Tubulin stabiliser
non-small cell lung carcinoma
PACLITAXEL POLIGLUMEXApproved
Tubulin stabiliser
neoplasm
PATUPILONEPhase III
Tubulin stabiliser
PF-06263507Phase I
Tubulin inhibitor
PINATUZUMAB VEDOTINPhase II
CD22 binding agent
diffuse large B-cell lymphoma
PLINABULINPhase III
Tubulin inhibitor
non-small cell lung carcinoma
PLOCABULINPhase II
Tubulin inhibitor
colorectal cancer
POLATUZUMAB VEDOTINApproved
Tubulin inhibitor
diffuse large B-cell lymphoma
PRALUZATAMAB RAVTANSINEPhase II
Tubulin inhibitor
neoplasm
RG-7598Phase I
Fc receptor-like protein 5 binding agent
multiple myeloma
RG-7600Phase I
Tubulin inhibitor
ovarian cancer
RG-7636Phase I
Tubulin inhibitor
melanoma
RG-7841Phase I
Lymphocyte antigen 6E binding agent
SAGOPILONEPhase II
Tubulin stabiliser
breast cancer
SAR-566658Phase II
Tubulin inhibitor
triple-negative breast cancer
SOBLIDOTINPhase II
Tubulin inhibitor
SOFITUZUMAB VEDOTINPhase I
Mucin-16 binding agent
fallopian tube cancer
T-900607Phase II
Tubulin disrupting agent
hepatocellular carcinoma
TELISOTUZUMAB VEDOTINPhase III
Hepatocyte growth factor receptor binding agent
non-small cell lung carcinoma
TISOTUMAB VEDOTINApproved
Coagulation factor III binding agent
cervical cancer
TRASTUZUMAB BOTIDOTINPhase III
Tubulin inhibitor
HER2 Positive Breast Carcinoma
TRASTUZUMAB EMTANSINEApproved
Receptor protein-tyrosine kinase erbB-2 binding agent
TUSAMITAMAB RAVTANSINEPhase III
Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
non-small cell lung carcinoma
VANDORTUZUMAB VEDOTINPhase I
Metalloreductase STEAP1 binding agent
prostate cancer
VERUBULINPhase II
Tubulin disrupting agent
VINBLASTINEApproved
Tubulin inhibitor
VINBLASTINE SULFATEApproved
Tubulin inhibitor
lymphoma
VINCRISTINEApproved
Tubulin inhibitor
VINCRISTINE SULFATEApproved
Tubulin inhibitor
VINFLUNINEApproved
Tubulin inhibitor
VINFLUNINE DITARTRATEApproved
Tubulin inhibitor
benign urinary system neoplasm
VINORELBINEApproved
Tubulin inhibitor
VINORELBINE TARTRATEApproved
Tubulin inhibitor
VORSETUZUMAB MAFODOTINPhase I
Tubulin inhibitor
renal cell carcinoma